Year |
Citation |
Score |
2023 |
Pilewski KA, Wall S, Richardson SI, Manamela NP, Clark K, Hermanus T, Binshtein E, Venkat R, Sautto GA, Kramer KJ, Shiakolas AR, Setliff I, Salas J, Mapengo RE, Suryadevara N, ... ... Bailey JR, et al. Functional HIV-1/HCV cross-reactive antibodies isolated from a chronically co-infected donor. Cell Reports. 42: 112044. PMID 36708513 DOI: 10.1016/j.celrep.2023.112044 |
0.408 |
|
2022 |
Pfaff-Kilgore JM, Davidson E, Kadash-Edmondson K, Hernandez M, Rosenberg E, Chambers R, Castelli M, Clementi N, Mancini N, Bailey JR, Crowe JE, Law M, Doranz BJ. Sites of vulnerability in HCV E1E2 identified by comprehensive functional screening. Cell Reports. 39: 110859. PMID 35613596 DOI: 10.1016/j.celrep.2022.110859 |
0.331 |
|
2021 |
Quinn JR, Goyal A, Ribeiro RM, Massaccesi G, Bailey JR, Thomas DL, Balagopal A. Antiretroviral therapy for HIV and intrahepatic hepatitis C virus replication. Aids (London, England). PMID 34690280 DOI: 10.1097/QAD.0000000000003116 |
0.475 |
|
2021 |
Skinner NE, Vergara C, El-Diwany R, Paul H, Skaist A, Wheelan SJ, Thomas DL, Ray SC, Balagopal A, Bailey JR. Decreased Activated CD4 T Cell Repertoire Diversity After Antiretroviral Therapy in HIV-1/HCV Coinfection Correlates with CD4 T Cell Recovery. Viral Immunology. PMID 34672777 DOI: 10.1089/vim.2021.0027 |
0.505 |
|
2021 |
Veenhuis RT, Garliss CC, Bailey JR, Blankson JN. CD8 Effector T Cells Function Synergistically With Broadly Neutralizing Antibodies to Enhance Suppression of HIV Infection. Frontiers in Immunology. 12: 708355. PMID 34394110 DOI: 10.3389/fimmu.2021.708355 |
0.569 |
|
2020 |
May ME, Pohlmeyer CW, Kwaa AK, Mankowski MC, Bailey JR, Blankson JN. Combined Effects of HLA-B*57/5801 Elite Suppressor CD8+ T Cells and NK Cells on HIV-1 Replication. Frontiers in Cellular and Infection Microbiology. 10: 113. PMID 32266164 DOI: 10.3389/Fcimb.2020.00113 |
0.621 |
|
2020 |
Flyak AI, Ruiz SE, Salas J, Rho S, Bailey JR, Bjorkman PJ. An ultralong CDRH2 in HCV neutralizing antibody demonstrates structural plasticity of antibodies against E2 glycoprotein. Elife. 9. PMID 32125272 DOI: 10.7554/Elife.53169 |
0.327 |
|
2020 |
Skinner NE, Bailey JR. Broadly neutralizing antibodies against hepatitis C virus: location, location, location. Journal of Hepatology. PMID 32019681 DOI: 10.1016/J.Jhep.2020.01.005 |
0.33 |
|
2019 |
Kinchen VJ, Massaccesi G, Flyak AI, Mankowski MC, Colbert MD, Osburn WO, Ray SC, Cox AL, Crowe JE, Bailey JR. Plasma deconvolution identifies broadly neutralizing antibodies associated with hepatitis C virus clearance. The Journal of Clinical Investigation. 130. PMID 31408439 DOI: 10.1172/Jci130720 |
0.342 |
|
2019 |
Colbert MD, Flyak AI, Ogega CO, Kinchen VJ, Massaccesi G, Hernandez M, Davidson E, Doranz BJ, Cox AL, Crowe JE, Bailey JR. Broadly neutralizing antibodies targeting new sites of vulnerability in hepatitis C virus E1E2. Journal of Virology. PMID 31068427 DOI: 10.1128/Jvi.02070-18 |
0.345 |
|
2019 |
Bailey JR, Urbanowicz RA, Ball JK, Law M, Foung SKH. Standardized Method for the Study of Antibody Neutralization of HCV Pseudoparticles (HCVpp). Methods in Molecular Biology (Clifton, N.J.). 1911: 441-450. PMID 30593644 DOI: 10.1007/978-1-4939-8976-8_30 |
0.315 |
|
2019 |
Flyak AI, Ruiz S, Colbert M, Luong T, Crowe JE, Bailey JR, Bjorkman PJ. Abstract B109: Broadly neutralizing antibodies against HCV use a CDRH3 disulfide motif to recognize an E2 glycoprotein site that can be targeted for vaccine design Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-B109 |
0.31 |
|
2018 |
Kinchen VJ, Zahid MN, Flyak AI, Soliman MG, Learn GH, Wang S, Davidson E, Doranz BJ, Ray SC, Cox AL, Crowe JE, Bjorkman PJ, Shaw GM, Bailey JR. Broadly Neutralizing Antibody Mediated Clearance of Human Hepatitis C Virus Infection. Cell Host & Microbe. 24: 717-730.e5. PMID 30439341 DOI: 10.1016/J.Chom.2018.10.012 |
0.392 |
|
2018 |
Bailey JR, Barnes E, Cox AL. Approaches, Progress, and Challenges to Hepatitis C Vaccine Development. Gastroenterology. PMID 30268785 DOI: 10.1053/J.Gastro.2018.08.060 |
0.34 |
|
2018 |
Veenhuis RT, Kwaa AK, Garliss CC, Latanich R, Salgado M, Pohlmeyer CW, Nobles CL, Gregg J, Scully EP, Bailey JR, Bushman FD, Blankson JN. Long-term remission despite clonal expansion of replication-competent HIV-1 isolates. Jci Insight. 3. PMID 30232278 DOI: 10.1172/Jci.Insight.122795 |
0.614 |
|
2018 |
Kandathil AJ, Sugawara S, Goyal A, Durand CM, Quinn J, Sachithanandham J, Cameron AM, Bailey JR, Perelson AS, Balagopal A. No recovery of replication-competent HIV-1 from human liver macrophages. The Journal of Clinical Investigation. PMID 30198905 DOI: 10.1172/Jci121678 |
0.597 |
|
2018 |
Kinchen VJ, Bailey JR. Defining Breadth of Hepatitis C Virus Neutralization. Frontiers in Immunology. 9: 1703. PMID 30116237 DOI: 10.3389/Fimmu.2018.01703 |
0.345 |
|
2018 |
El-Diwany R, Soliman M, Sugawara S, Breitwieser F, Skaist A, Coggiano C, Sangal N, Chattergoon M, Bailey JR, Siliciano RF, Blankson JN, Ray SC, Wheelan SJ, Thomas DL, Balagopal A. CMPK2 and BCL-G are associated with type 1 interferon-induced HIV restriction in humans. Science Advances. 4: eaat0843. PMID 30083606 DOI: 10.1126/Sciadv.Aat0843 |
0.718 |
|
2018 |
Kinchen VJ, Cox AL, Bailey JR. Can Broadly Neutralizing Monoclonal Antibodies Lead to a Hepatitis C Virus Vaccine? Trends in Microbiology. PMID 29703495 DOI: 10.1016/J.Tim.2018.04.002 |
0.348 |
|
2017 |
Mankowski MC, Kinchen VJ, Wasilewski LN, Flyak AI, Ray SC, Crowe JE, Bailey JR. Synergistic anti-HCV broadly neutralizing human monoclonal antibodies with independent mechanisms. Proceedings of the National Academy of Sciences of the United States of America. PMID 29255018 DOI: 10.1073/Pnas.1718441115 |
0.335 |
|
2017 |
Bailey JR, Flyak AI, Cohen VJ, Li H, Wasilewski LN, Snider AE, Wang S, Learn GH, Kose N, Loerinc L, Lampley R, Cox AL, Pfaff JM, Doranz BJ, Shaw GM, et al. Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance. Jci Insight. 2. PMID 28469084 DOI: 10.1172/Jci.Insight.92872 |
0.375 |
|
2017 |
El-Diwany R, Cohen VJ, Mankowski MC, Wasilewski LN, Brady JK, Snider AE, Osburn WO, Murrell B, Ray SC, Bailey JR. Extra-epitopic hepatitis C virus polymorphisms confer resistance to broadly neutralizing antibodies by modulating binding to scavenger receptor B1. Plos Pathogens. 13: e1006235. PMID 28235087 DOI: 10.1371/Journal.Ppat.1006235 |
0.333 |
|
2017 |
Walker-Sperling VE, Pohlmeyer CW, Veenhuis RT, May M, Luna KA, Kirkpatrick AR, Laeyendecker O, Cox AL, Carrington M, Bailey JR, Arduino RC, Blankson JN. Factors Associated With the Control of Viral Replication and Virologic Breakthrough in a Recently Infected HIV-1 Controller. Ebiomedicine. PMID 28159573 DOI: 10.1016/J.Ebiom.2017.01.034 |
0.714 |
|
2016 |
Wasilewski L, Ray S, Bailey JR. Hepatitis C virus resistance to broadly neutralizing antibodies measured using replication competent virus and pseudoparticles. The Journal of General Virology. PMID 27667373 DOI: 10.1099/Jgv.0.000608 |
0.404 |
|
2016 |
Keck ZY, Wang Y, Lau P, Lund G, Rangarajan S, Fauvelle C, Liao GC, Holtsberg FW, Warfield KL, Aman MJ, Pierce BG, Fuerst TR, Bailey JR, Baumert TF, Mariuzza RA, et al. Affinity maturation of a broadly neutralizing human monoclonal antibody that prevents acute HCV infection. Hepatology (Baltimore, Md.). PMID 27641232 DOI: 10.1002/Hep.28850 |
0.404 |
|
2016 |
Wasilewski LN, El-Diwany R, Munshaw S, Snider AE, Brady JK, Osburn WO, Ray SC, Bailey JR. A hepatitis C virus envelope polymorphism confers resistance to neutralization by polyclonal sera and broadly neutralizing monoclonal antibodies. Journal of Virology. PMID 26819308 DOI: 10.1128/Jvi.02837-15 |
0.353 |
|
2015 |
El-Diwany R, Wasilewski L, Witwer KW, Bailey JR, Page K, Ray SC, Cox AL, Thomas DL, Balagopal A. Acute Hepatitis C Virus Infection Induces Consistent Changes in Circulating miRNAs that are Associated with Non-Lytic Hepatocyte Release. Journal of Virology. PMID 26157120 DOI: 10.1128/Jvi.00955-15 |
0.311 |
|
2015 |
Bailey JR, Dowd KA, Snider AE, Osburn WO, Mehta SH, Kirk GD, Thomas DL, Ray SC. CD4+ T-Cell-Dependent Reduction in Hepatitis C Virus-Specific Neutralizing Antibody Responses After Coinfection With Human Immunodeficiency Virus. The Journal of Infectious Diseases. PMID 25754978 DOI: 10.1093/Infdis/Jiv139 |
0.527 |
|
2015 |
Bailey JR, Wasilewski LN, Snider AE, El-Diwany R, Osburn WO, Keck Z, Foung SK, Ray SC. Naturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance. The Journal of Clinical Investigation. 125: 437-47. PMID 25500884 DOI: 10.1172/Jci78794 |
0.336 |
|
2014 |
Osburn WO, Snider AE, Wells BL, Latanich R, Bailey JR, Thomas DL, Cox AL, Ray SC. Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses. Hepatology (Baltimore, Md.). 59: 2140-51. PMID 24425349 DOI: 10.1002/Hep.27013 |
0.391 |
|
2013 |
Rabi SA, Laird GM, Durand CM, Laskey S, Shan L, Bailey JR, Chioma S, Moore RD, Siliciano RF. Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance. The Journal of Clinical Investigation. 123: 3848-60. PMID 23979165 DOI: 10.1172/Jci67399 |
0.678 |
|
2012 |
Bailey JR, Laskey S, Wasilewski LN, Munshaw S, Fanning LJ, Kenny-Walsh E, Ray SC. Constraints on viral evolution during chronic hepatitis C virus infection arising from a common-source exposure. Journal of Virology. 86: 12582-90. PMID 22973048 DOI: 10.1128/Jvi.01440-12 |
0.442 |
|
2012 |
Munshaw S, Bailey JR, Liu L, Osburn WO, Burke KP, Cox AL, Ray SC. Computational reconstruction of Bole1a, a representative synthetic hepatitis C virus subtype 1a genome. Journal of Virology. 86: 5915-21. PMID 22438535 DOI: 10.1128/Jvi.05959-11 |
0.451 |
|
2011 |
Salgado M, Rabi SA, O'Connell KA, Buckheit RW, Bailey JR, Chaudhry AA, Breaud AR, Marzinke MA, Clarke W, Margolick JB, Siliciano RF, Blankson JN. Prolonged control of replication-competent dual- tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy. Retrovirology. 8: 97. PMID 22141397 DOI: 10.1186/1742-4690-8-97 |
0.835 |
|
2011 |
Rabi SA, O'Connell KA, Nikolaeva D, Bailey JR, Jilek BL, Shen L, Page KR, Siliciano RF, Blankson JN. Unstimulated primary CD4+ T cells from HIV-1-positive elite suppressors are fully susceptible to HIV-1 entry and productive infection. Journal of Virology. 85: 979-86. PMID 21068257 DOI: 10.1128/Jvi.01721-10 |
0.797 |
|
2010 |
Salgado M, Brennan TP, O'Connell KA, Bailey JR, Ray SC, Siliciano RF, Blankson JN. Evolution of the HIV-1 nef gene in HLA-B*57 positive elite suppressors. Retrovirology. 7: 94. PMID 21059238 DOI: 10.1186/1742-4690-7-94 |
0.775 |
|
2010 |
Powell M, Bailey J, Maggio LA. Clinical inquiries. How should you manage children born to hepatitis C-positive women? The Journal of Family Practice. 59: 289-90. PMID 20544050 |
0.308 |
|
2010 |
O'Connell KA, Brennan TP, Bailey JR, Ray SC, Siliciano RF, Blankson JN. Control of HIV-1 in elite suppressors despite ongoing replication and evolution in plasma virus. Journal of Virology. 84: 7018-28. PMID 20444904 DOI: 10.1128/Jvi.00548-10 |
0.778 |
|
2009 |
O'Connell KA, Bailey JR, Blankson JN. Elucidating the elite: mechanisms of control in HIV-1 infection. Trends in Pharmacological Sciences. 30: 631-7. PMID 19837464 DOI: 10.1016/J.Tips.2009.09.005 |
0.787 |
|
2009 |
Lassen KG, Lobritz MA, Bailey JR, Johnston S, Nguyen S, Lee B, Chou T, Siliciano RF, Markowitz M, Arts EJ. Elite suppressor-derived HIV-1 envelope glycoproteins exhibit reduced entry efficiency and kinetics. Plos Pathogens. 5: e1000377. PMID 19360131 DOI: 10.1371/Journal.Ppat.1000377 |
0.826 |
|
2009 |
Bailey JR, Brennan TP, O'Connell KA, Siliciano RF, Blankson JN. Evidence of CD8+ T-cell-mediated selective pressure on human immunodeficiency virus type 1 nef in HLA-B*57+ elite suppressors. Journal of Virology. 83: 88-97. PMID 18945771 DOI: 10.1128/Jvi.01958-08 |
0.809 |
|
2008 |
Bailey JR, O'Connell K, Yang HC, Han Y, Xu J, Jilek B, Williams TM, Ray SC, Siliciano RF, Blankson JN. Transmission of human immunodeficiency virus type 1 from a patient who developed AIDS to an elite suppressor. Journal of Virology. 82: 7395-410. PMID 18495769 DOI: 10.1128/Jvi.00800-08 |
0.788 |
|
2008 |
Andrade A, Bailey JR, Xu J, Philp FH, Quinn TC, Williams TM, Ray SC, Thomas DL, Blankson JN. CD4+ T cell depletion in an untreated HIV type 1-infected human leukocyte antigen-B*5801-positive patient with an undetectable viral load. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 46: e78-82. PMID 18444844 DOI: 10.1086/529387 |
0.696 |
|
2008 |
Gandhi SK, Siliciano JD, Bailey JR, Siliciano RF, Blankson JN. Role of APOBEC3G/F-mediated hypermutation in the control of human immunodeficiency virus type 1 in elite suppressors. Journal of Virology. 82: 3125-30. PMID 18077705 DOI: 10.1128/Jvi.01533-07 |
0.694 |
|
2007 |
Bailey JR, Zhang H, Wegweiser BW, Yang HC, Herrera L, Ahonkhai A, Williams TM, Siliciano RF, Blankson JN. Evolution of HIV-1 in an HLA-B*57-positive patient during virologic escape. The Journal of Infectious Diseases. 196: 50-5. PMID 17538883 DOI: 10.1086/518515 |
0.82 |
|
2007 |
Blankson JN, Bailey JR, Thayil S, Yang HC, Lassen K, Lai J, Gandhi SK, Siliciano JD, Williams TM, Siliciano RF. Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. Journal of Virology. 81: 2508-18. PMID 17151109 DOI: 10.1128/Jvi.02165-06 |
0.833 |
|
2006 |
Lassen KG, Ramyar KX, Bailey JR, Zhou Y, Siliciano RF. Nuclear retention of multiply spliced HIV-1 RNA in resting CD4+ T cells. Plos Pathogens. 2: e68. PMID 16839202 DOI: 10.1371/Journal.Ppat.0020068 |
0.826 |
|
2006 |
Bailey JR, Sedaghat AR, Kieffer T, Brennan T, Lee PK, Wind-Rotolo M, Haggerty CM, Kamireddi AR, Liu Y, Lee J, Persaud D, Gallant JE, Cofrancesco J, Quinn TC, Wilke CO, et al. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. Journal of Virology. 80: 6441-57. PMID 16775332 DOI: 10.1128/Jvi.00591-06 |
0.824 |
|
2006 |
Bailey JR, Williams TM, Siliciano RF, Blankson JN. Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations. The Journal of Experimental Medicine. 203: 1357-69. PMID 16682496 DOI: 10.1084/Jem.20052319 |
0.686 |
|
2006 |
Bailey JR, Lassen KG, Yang HC, Quinn TC, Ray SC, Blankson JN, Siliciano RF. Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly active antiretroviral therapy. Journal of Virology. 80: 4758-70. PMID 16641269 DOI: 10.1128/Jvi.80.10.4758-4770.2006 |
0.835 |
|
2006 |
Blankson JN, Bailey JR, Siliciano RF. Crosscurrents in HIV-1 evolution. Nature Immunology. 7: 121-2. PMID 16424885 DOI: 10.1038/Ni0206-121 |
0.705 |
|
2005 |
Lassen KG, Ramyar KX, Bailey JR, Zhou Y, Siliciano RF. Retrovirology. 2: S74. DOI: 10.1186/1742-4690-2-S1-S74 |
0.817 |
|
2004 |
Lassen KG, Bailey JR, Siliciano RF. Analysis of human immunodeficiency virus type 1 transcriptional elongation in resting CD4+ T cells in vivo. Journal of Virology. 78: 9105-14. PMID 15308706 DOI: 10.1128/Jvi.78.17.9105-9114.2004 |
0.83 |
|
2004 |
Bailey J, Blankson JN, Wind-Rotolo M, Siliciano RF. Mechanisms of HIV-1 escape from immune responses and antiretroviral drugs. Current Opinion in Immunology. 16: 470-6. PMID 15245741 DOI: 10.1016/J.Coi.2004.05.005 |
0.721 |
|
Show low-probability matches. |